🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Chuck Royce’s DFTX Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+234,051 Shares
Current Position
234,051 Shares
$4.42 M Value

Chuck Royce's DFTX Position Overview

Chuck Royce (via Royce & Associates Lp) currently holds 234,051 shares of Definium Therapeutics, Inc. (DFTX) worth $4.42 M, representing 0.04% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Chuck Royce has initiated a new position in DFTX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Chuck Royce's Definium Therapeutics (DFTX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Definium Therapeutics (DFTX) Trades by Chuck Royce

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +234,051 New Buy 234,051 $18.90

Chuck Royce's Definium Therapeutics Investment FAQs

Chuck Royce first purchased Definium Therapeutics, Inc. (DFTX) in Q1 2026, acquiring 234,051 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Chuck Royce has held Definium Therapeutics, Inc. (DFTX) for 1 quarters since Q1 2026.

Chuck Royce's largest addition to Definium Therapeutics, Inc. (DFTX) was in Q1 2026, adding 234,051 shares worth $4.42 M.

According to the latest 13F filing for Q1 2026, Chuck Royce's firm, Royce & Associates Lp, owns 234,051 shares of Definium Therapeutics, Inc. (DFTX), valued at approximately $4.42 M.

As of the Q1 2026 filing, Definium Therapeutics, Inc. (DFTX) represents approximately 0.04% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.

Chuck Royce's peak holding in Definium Therapeutics, Inc. (DFTX) was 234,051 shares, as reported at the end of Q1 2026.